Exclusive: Nothing slashes jobs in cost-cutting push July 24, 2026 British smartphone maker Nothing has begun slashing jobs across its global business as it looks to cut costs following a rapid hiring spree, City AM can reveal. The Kings Cross headquartered hardware firm, founded by Carl Pei, who previously set up Chinese smartphone company OnePlus, has begun consultations with staff across regions and has already [...]
U.K. Enterprises Adopt AI-Augmented Operations July 24, 2026 Organizations prioritize governed AI, employee experience and measurable productivity outcomes as workplace transformation matures, ISG Provider Lens® report says
Comsysto Reply Supports Audi in Evolving Its B2B Used Car Platform With an AI-Based Multi-Agent System July 24, 2026 Comsysto Reply, the Reply Group company specialised in agile software development and cloud-native solutions, has partnered with Audi on the ongoing development of its “Used Car Platform”, the company’s central digital marketplace for B2B used car trading. A tailored multi-agent solution accelerates software development, reduces repetitive activities, and enables faster delivery of new features. This [...]
Almirall H1 2026 Results July 24, 2026 Almirall delivers solid H1 2026 results growing Net Sales by 7.5% and EBITDA by 23.7%, driven by its strong European Dermatology business – reiterating guidance aligned with long-term growth trajectory Net Sales increased by 7.5% YoY to €602.7 MM, while EBITDA grew by 23.7% to €150.7 MM, reflecting strong commercial and operational execution. The European Dermatology business continues to drive growth, increasing 18.1% YoY to €341.9 MM, supported by strong performance of its key growth drivers and favourable underlying market growth. Continued solid performance of the biologics portfolio, with Ilumetri® delivering 10.5% increase to €125.2 MM and Ebglyss® growing 88.2% to €84.5 MM in Net Sales, supported by sustained growth in recent launch markets. The broader dermatology portfolio delivers positive performance, including Wynzora® (19.3%, total of €20.4 MM) and Klisyri® (13.9%, total of €15.6 MM). Almirall advances its innovation strategy through progress across its R&D pipeline, including four ongoing PoC/Phase II studies and two additional PoC studies planned to be initiated by end of 2026, targeting five dermatological diseases. The first readouts are expected towards the end of 2026. Almirall signs a strategic research collaboration and licensing agreement with Certest Biotec to discover and develop novel treatments for rare dermatologic diseases and recurrent cutaneous conditions. Reiterated guidance for the full year 2026: 9-12% growth and € 270MM to € 290MM EBITDA.
A beginner’s guide to appeasing the bond market – and why it matters July 24, 2026 Britain’s enormous debt pile means the bond market now has the power to decide the fate of a government. Ali Lyon spoke to gilt investors to see how our new Chancellor can keep them happy. When John Healey was last in the Treasury, the world was a very different place. Britain’s economy was growing at [...]
Burnham accused of gutting tech department’s ‘biggest strength’ July 23, 2026 Andy Burnham’s decision to abolish the Department for Science, Innovation and Technology (DSIT) will split up the teams it was created to bring together, according to its former top civil servant. A leaked internal government document shows AI, digital and science responsibilities being divided between three departments as ministers begin dismantling DSIT less than three [...]
Sport documentaries muddle grey area of storytelling vs reality July 23, 2026 As every sport seemingly gets its own documentary, Matt Readman assesses whether they’re meddling with reality. There is a famous rule in nature documentary filmmaking: observe, but never intervene. The moment the camera changes the behaviour of its subject, it stops documenting reality and starts creating it. Earlier this month the International Cricket Council investigated [...]
Francisco Partners Closes $21 Billion Across Flagship and Agility Funds July 23, 2026 Largest fundraise in the firm’s history brings total capital raised to more than $75 billion
AI spending overshadows Alphabet and Tesla earnings July 23, 2026 Wall Street’s biggest tech companies delivered another round of strong earnings on Wednesday, but the primary focus for investors is the growing cost of the artificial intelligence race. Alphabet and Tesla beat revenue expectations, yet their shares fell in after-hours trading after both companies signalled another year of heavy spending on AI infrastructure. Google-owner Alphabet [...]
I’m an editor. This is the most worrying thing about AI slop July 23, 2026 The slow creep of AI slop is unnerving to witness I’m an editor at this newspaper. Over the past week or so some of our best contributors have filed me AI slop – but not quite how you’d imagine it. These pieces aren’t necessarily completely written by AI, although sometimes they are. The new frontier [...]